Consensus CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
55.05 ^USD	-1.98%		-9.26%	-12.06%

Apr. 18	Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	MT
Apr. 17	Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	MT

Evolution of the average Target Price on CRISPR Therapeutics AG

Price target over the last 5 years

History of analyst recommendation changes

7b0568fc9435f4103735dbac.Fx8WWW_LwNn7_aRPvdzdihrHuT6ZANIbmm_Sdcc7OSo.clt5HRyRqKuTxeogxZbq3GmwwUagOIZv0jjkAbRDWBMiJyA-VqD5nrHO_Q~032bf1daa1b267b81bcc867165e1f4d6

Analyst Recommendations on CRISPR Therapeutics AG

Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	Apr. 18	MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	Apr. 17	MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating	Mar. 06	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating	Feb. 26	MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating	Feb. 22	MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating	Feb. 22	MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating	Feb. 22	MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept	Feb. 22	MT
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating	Feb. 21	MT
Wolfe Research Starts Coverage on CRISPR Therapeutics With Peer Perform Rating	Feb. 15	MT
Kempen Downgrades CRISPR Therapeutics to Neutral From Buy, Cuts Price Target to $65 From $80	Dec. 22	MT
Morgan Stanley Lifts Price Target on CRISPR Therapeutics to $46 From $42, Keeps Underweight Rating	Dec. 12	MT
Truist Securities Adjusts Price Target on CRISPR Therapeutics to $160 From $220, Maintains Buy Rating	Dec. 11	MT
Needham Raises CRISPR Therapeutics' Price Target to $88 From $85, Keeps Buy Rating	Dec. 11	MT
Barclays Raises Price Target on CRISPR Therapeutics to $61 From $56, Maintains Equalweight Rating	Dec. 11	MT
TD Cowen Downgrades CRISPR Therapeutics to Underperform From Market Perform, $30 Price Target	Dec. 11	MT
RBC Lifts Price Target on CRISPR Therapeutics to $57 From $50 After US FDA Approval of CASGEVY for Sickle Cell Disease; Sector Perform, Speculative Risk Kept	Dec. 11	MT
JMP Securities Raises Price Target on CRISPR Therapeutics to $80 From $74, Keeps Market Outperform Rating	Dec. 11	MT
Joe Biden and Xi Jinping almost made up	Nov. 16
Morgan Stanley Trims Price Target on CRISPR Therapeutics to $42 From $43, Keeps Underweight Rating	Nov. 13	MT
Needham Cuts Price Target on CRISPR Therapeutics to $85 From $88, Maintains Buy Rating	Nov. 07	MT
RBC Cuts Price Target on CRISPR Therapeutics to $50 From $55, Keeps Sector Perform, Speculative Risk	Nov. 07	MT
Mizuho Securities Initiates CRISPR Therapeutics With Buy Rating	23-09-27	MT
Citigroup Upgrades CRISPR Therapeutics to Buy From Neutral, Price Target is $70	23-08-18	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $43 From $42, Maintains Underweight Rating	23-08-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

55.05 USD

Average target price

88.12 USD

Spread / Average Target

+60.08%

High Price Target

199 USD

Spread / Highest target

+261.49%

Low Price Target

30 USD

Spread / Lowest Target

-45.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CRISPR Therapeutics AG

Citigroup
Mizuho Securities
Morgan Stanley
Wells Fargo Securities
Barclays
Chardan Research
RBC Capital Markets
Needham & Co.
Wolfe Research
Kempen
Truist Securities
TD Cowen
JMP Securities
Credit Suisse
William Blair & Co.
Stifel Nicolaus
Cantor Fitzgerald
Piper Sandler
Bernstein
Baird
Oppenheimer
EF Hutton
SVB Securities LLC
Goldman Sachs
Evercore ISI
BMO Capital
SVB Leerink
Brookline Capital Markets
Cowen
SMBC Nikko
Canaccord Genuity
Chardan
Jefferies & Co.

Ratings for CRISPR Therapeutics AG

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar